-$0.55 Earnings Per Share Expected for Axovant Sciences Ltd (AXON) This Quarter
Wall Street brokerages expect Axovant Sciences Ltd (NYSE:AXON) to report ($0.55) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Axovant Sciences’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.65). Axovant Sciences posted earnings of ($0.39) per share during the same quarter last year, which suggests a negative year over year growth rate of 41%. The firm is expected to report its next quarterly earnings results on Monday, November 6th.
On average, analysts expect that Axovant Sciences will report full-year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.38) to ($1.77). For the next fiscal year, analysts expect that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.98) to ($1.14). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Axovant Sciences.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12).
A number of analysts have recently commented on the company. Oppenheimer Holdings, Inc. lowered Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Evercore ISI restated an “outperform” rating and issued a $9.00 price target (down from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Piper Jaffray Companies lowered Axovant Sciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $32.00 to $9.00 in a report on Tuesday, September 26th. Finally, Jefferies Group LLC assumed coverage on Axovant Sciences in a report on Monday, July 10th. They set a “buy” rating and a $40.00 target price on the stock. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $14.13.
A number of hedge funds and other institutional investors have recently made changes to their positions in AXON. Wells Fargo & Company MN increased its position in Axovant Sciences by 34.3% during the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock worth $335,000 after buying an additional 5,733 shares during the last quarter. American International Group Inc. increased its position in Axovant Sciences by 7.1% during the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in Axovant Sciences during the first quarter worth approximately $219,000. Bank of America Corp DE increased its position in Axovant Sciences by 38.9% during the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in Axovant Sciences by 1,718.3% during the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares during the last quarter.
Shares of Axovant Sciences (NYSE AXON) opened at $5.26 on Friday. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.01 and a current ratio of 6.01.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.